FDA inks $49.9 million deal with SAS
CARY, N.C., Jan. 11, 2021 /PRNewswire/ -- SAS, the leader in advanced analytics, will extend a 40-year partnership with the US Food and Drug Administration (FDA) to expand its capabilities in natural language processing, artificial intelligence and machine learning capabilities through the SAS® Viya® platform in support of the FDA's mission as an essential public health agency. Through a five-year, $49.9 million Blanket Purchase Agreement (BPA), SAS will support bold digital transformation efforts underway in the FDA.
The initial projects will be with the FDA's Center for Drug Evaluation and Research (CDER), which helps to ensure that human drugs are safe and effective for their intended use. Through the SAS partnership, the FDA will:
A longtime customer with a large and experienced SAS user community and many mission-critical SAS applications, the FDA will take advantage of the BPA to consolidate and expand its use of SAS utilizing the SAS Platform powered by SAS Viya, the company's flagship cloud-based AI and machine learning platform. SAS will embed analytics experts within the FDA to help manage and identify modernization opportunities, within CDER and other areas of the agency.
"We are in a new era of drug regulation," said SAS CEO Jim Goodnight. "By unleashing the power of SAS' most advanced technologies, we can work together to help the FDA find the perfect combination of speed, efficacy and safety when it comes to getting lifesaving drugs to Americans."
The BPA builds on decades of collaboration between the FDA, SAS and US Department of Health and Human Services (HHS). HHS uses SAS software extensively in several other agencies, including Centers for Disease Control and Prevention, National Institutes of Health, and Centers for Medicare and Medicaid Services. SAS is used in numerous applications for disease surveillance, food and drug safety, combatting the opioid crisis, Medicare fraud and abuse, and other enterprise performance management initiatives throughout HHS.
SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. ® indicates USA registration. Other brand and product names are trademarks of their respective companies. Copyright © 2021 SAS Institute Inc. All rights reserved.
View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-inks-49-9-million-deal-with-sas-301205098.html